Understanding Platelets to Prevent Heart Attacks and Strokes
CD37 as a Regulator of Platelet Patho(Physiological) Responses
This research looks for new ways to prevent heart attacks and strokes by understanding how tiny blood cells called platelets contribute to these serious conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11109499 on NIH RePORTER |
What this research studies
Heart attacks and strokes are often caused by platelets, which are small cells in our blood. While medicines exist to prevent these events, they can also increase the risk of bleeding, especially for people who haven't had a heart attack or stroke yet. This work aims to find new ways to target platelets that could prevent these events without causing dangerous bleeding. We are focusing on a newly identified protein called CD37 to see how it controls platelet activity and if it could be a safe new target for future treatments.
Who could benefit from this research
Good fit: This foundational research is for future patients at risk of heart attacks and strokes who could benefit from new preventative strategies.
Not a fit: Patients currently undergoing treatment for active bleeding or those not at risk for atherosclerotic cardiovascular disease may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new, safer treatments to prevent first heart attacks and strokes for people at risk, without the high bleeding complications of current therapies.
How similar studies have performed: While antiplatelet therapies are well-established, this approach investigates a novel platelet target, CD37, which represents a new direction for primary prevention.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Barrett, Tessa — New York University School of Medicine
- Study coordinator: Barrett, Tessa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.